Should You Buy Davita Inc (DVA) Stock After it Is Up 5.16% in a Week?

Davita Inc (DVA) stock is up 5.16% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Davita Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on DVA!

See Full DVA Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With DVA Stock Today?

Davita Inc (DVA) stock is trading at $104.38 as of 2:25 PM on Friday, Dec 1, an increase of $2.92, or 2.88% from the previous closing price of $101.46. The stock has traded between $100.56 and $104.90 so far today. Volume today is light. So far 618,785 shares have traded compared to average volume of 1,400,672 shares.

More About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business. Click Here to get the full Stock Report for Davita Inc stock.